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Abstract
Background: Our goal was to illustrate a method for making indirect treatment comparisons in the absence of
head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related
opportunistic infections.
Results: We identified published results of randomized controlled trials from the United States in which HIV-infected
patients received rifabutin, azithromycin, clarithromycin, or placebo for prophylaxis against Mycobacterium avium
complex (MAC). We extracted the number of subjects, follow-up time, primary MAC events, mean CD4 count, and
proportion of subjects on mono or dual antiretroviral therapy (ART) from each study. We derived the efficacy of each
drug using adjusted indirect comparisons and, when possible, by direct comparisons. Five articles satisfied our inclusion
criteria. Using direct comparison, we estimated the efficacies of rifabutin, clarithromycin, and azithromycin compared to
placebo to be 53% (95% CI, 48-61%), 66% (95% CI, 61-74%), and 66% (95% CI, 60-81%), respectively. Using adjusted
indirect calculations, the efficacy of rifabutin compared to placebo ranged from 41% to 44%. The adjusted indirect
efficacies of clarithromycin and azithromycin were estimated to be 73% and 72%, respectively.
Conclusions: Accurate estimates of specific drug dosages as compared to placebo are important for policy and
implementation research. This study illustrates a simple method of adjusting for differences in study populations by
using indirect comparisons in the absence of head-to-head HIV clinical trials.
Background
Cost-effectiveness analyses are frequently used to guide
health policy decisions, particularly in HIV disease[1-3].
To offer long term projections on clinical and economic
implications to specific treatment strategies and to
address the need to make clinical decisions where
evidence from published studies is insufficient, cost-
effectiveness analyses offer strategic insights using
model-based evaluations. Models used in cost-effective-
ness analyses are often multidimensional and based on a
large number of input parameters. In such model-based
evaluations, efficacy estimates of drug regimens com-
pared to placebo are critical for accurate delineation of
alternative treatment strategies and cost-effectiveness
comparisons. However, head-to-head placebo-controlled
trials often are not feasible; they are expensive, time-con-
suming, and unethical if guidelines for a pharmaceutical
intervention already exist [4]. Adjusted indirect comparison
of randomized controlled trials has become an increasingly
accepted method for assessing the effect of pharmaceutical
interventions on survival outcomes, in the absence of pla-
cebo-controlled trials [5-8]. Within the framework of a
cost-effectiveness model, often based on hundreds of para-
meters, it is not always feasible to use complex methods to
derive every input parameter, especially for parameters not
likely to affect major policy decisions.
Our goal was to illustrate a simple method for adjust-
ing drug efficacy estimates according to differences in
disease severity to derive parameters for a complex com-
puter simulation model of HIV disease [1,9]. One study,
for example, may compare regimen A to regimen B, and
another study may compare regimen B to placebo.
Adjusted indirect comparison provides a method for
establishing the efficacy of regimen A compared to
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randomization.
Previous studies using adjusted indirect comparison
estimated one-time probabilities and pooled the effica-
cies of drug regimens with varying doses [5,7,10,11].
Here, we establish a method for determining the efficacy
of specific drug doses over time, thus allowing for pre-
dictions of treatment failure after any duration of ther-
apy. We focused our illustration on prophylactic drugs
for Mycobacterium avium complex (MAC) in patients
infected with the human immunodeficiency virus (HIV)
in the United States, because national guidelines recom-
mend administering specific drugs and doses to prevent
MAC [12]. Moreover, we also selected MAC as our
illustration because of the availability of placebo-con-
trolled trials for each guideline-recommended drug.
Methods
Study selection
We performed a MEDLINE search to identify randomized
controlled trials of primary prophylaxis against MAC that
were consistent with the current United States prophylaxis
guidelines for HIV-infected patients[12]. We used the fol-
lowing search terms: Mycobacterium avium complex, ran-
domized-controlled trial, placebo, rifabutin, azithromycin,
and clarithromycin. We then reviewed the bibliographies
of selected articles to identify other relevant studies. We
considered data from randomized controlled clinical trials
that reported follow-up time and administered primary
prophylaxis for MAC, using one of the following drug
regimens: 300 mg rifabutin once daily, 1200 mg azithro-
mycin once weekly, or 500 mg clarithromycin twice daily.
These doses are based on the 2009 “Guidelines for Preven-
tion and Treatment of Opportunistic Infections in HIV-
infected Adults and Adolescents” [12]. To be included in
this analysis, studies had to have at least two treatment
arms and compare prophylactic regimens either to placebo
directly, or to one another. Data on the number of sub-
jects, follow-up time, and primary MAC events are
included in Table 1. We collected additional data on mean
C D 4c o u n t ,n u m b e ro fp a t i e n t so nm o n oo rd u a la n t i r e -
troviral therapy (ART), endpoint definitions, and inclusion
or exclusion criteria from each study. For one pair of iden-
tically designed studies, we derived efficacy using the
weighted averages of data from the two studies [13].
Direct comparison
If Trial 1 compared regimen A to placebo, we used
Equation 1 to derive the efficacy of regimen A relative
to placebo.
EfﬁcacyA =1−
MonthlyProboffailureA
MonthlyproboffailurePlacebo
(1)
We determined the two-sided 95% confidence interval
(CI) of each efficacy derived by direct comparison.
Adjusted indirect comparison
When direct comparison of a drug regimen to placebo
was not possible, we made adjusted indirect compari-
sons. For example, when trial 1 compared regimen A to
placebo, and trial 2 compared regimen B to regimen A,
we computed a “correction” factor to adjust for differ-
ences in baseline characteristic differences, including
mean CD4 count and number of patients on ART,
between the subjects of trial 1 and trial 2. The correc-
tion factor preserved the balance between the two ran-
domized groups. Using Equation 2, we derived a
correction factor to compare regimen A of trial 2 to
regimen A of trial 1.
Correction FactorA =
MonthlyproboffailureA,trial2
MonthlyproboffailureA,trial1 (2)
We then used Equation 3 to calculate the adjusted
monthly probability of failure of regimen B.
AdjustedmonthlyproboffailureB = (Correction factorA)∗(MonthlyProboffailureB)(3)
This adjusted monthly probability of failure allowed us
to compare regimen B in trial 2 to placebo in trial 1.
We obtained the efficacy of regimen B using Equation 4.
EfﬁcacyB =1−
AdjustedmonthlyproboffailureB
MonthlyproboffailurePlacebo
(4)
We compared the direct and adjusted indirect effica-
cies of each regimen to assess the validity of adjusted
indirect comparisons.
Results
Characteristics of eligible trials
We identified five eligible randomized controlled trials
that included a total of 3,222 subjects (Table 1). Three stu-
dies compared one drug regimen to placebo, and two trials
compared different prophylaxis regimens to each other.
Efficacy by direct comparison
We used data from three studies, by Nightingale et al.,
Pierce et al., and Oldfield et al.t oc o m p a r er i f a b u t i n ,
clarithromycin, and azithromycin to placebo, directly
(Table 2) [13-15]. The absolute efficacies of rifabutin,
clarithromycin, and azithromycin, each compared to pla-
cebo, were estimated to be 53% (95% CI, 48-61%), 66%
(95% CI, 61-74%), and 66% (95% CI, 60-81%).
Efficacy by indirect comparison
After adjusting the failure rate of rifabutin in the Benson
et al. study to baseline characteristics in the Pierce et al.
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of rifabutin in Benson et al. to be 41%. Similarly, we com-
pared rifabutin in Havlir et al. to placebo in Oldfield et al.,
because both studies contained one azithromycin arm
[15,17]. The efficacy of rifabutin in Havlir et al. was 44%,
compared to placebo in Oldfield et al.
When we adjusted the results of the Benson et al.
study to baseline characteristics in Nightingale et al.,
using the rifabutin arms in each study, we estimated the
efficacy of clarithromycin in Benson et al. compared to
placebo in Nightingale et al. to be 73% [13,16]. When
we adjusted the results of the Havlir et al.s t u d yt o
Table 1 Characteristics of 5 randomized controlled trials of primary prophylaxis against Mycobacterium avium complex
in HIV-infected adults
Study Drug dose No.
subjects
Mean CD4
Count
a
(cells/μl)
%O n
ART
Median Follow-
up time
b (days)
Primary MAC
events (N)
Direct monthly
failure rate
(95% CI)
Direct
monthly
probability
of failure
Nightingale 1993, study
023 and 027
c [13]
Rifabutin, 300
mg, qd
283 64 100 209
d 24 0.012 (0.007-0.017) 0.012
Placebo 290 56 100 202
d 51 0.027 (0.019-0.0034) 0.026
Havlir 1996 [17] Rifabutin, 300
mg, qd
223 47 – 514 52 0.014 (0.010-0.018) 0.014
Azithromycin,
1200 mg, qwk
223 49 – 514 31 0.008 (0.005-0.011) 0.008
Benson 2000 [16] Rifabutin, 300
e
mg, qd
391 30 75 574 59 0.008 (0.006-0.010) 0.008
Clarithromycin,
500 mg, bid
398 27 73 595 36 0.005 (0.003-0.006) 0.005
Pierce 1996 [14] Clarithromycin,
500 mg, bid
333 30 – 427
f 19 0.004 (0.002-0.006) 0.004
Placebo 334 25 – 402
f 53 0.012 (0.009-0.015) 0.012
Oldfield 1998 [15] Azithromycin,
1200 mg, qwk
85 44 – 400
d 9
g 0.008 (0.003-0.013) 0.008
Placebo 89 44 – 340
d 24
g 0.024 (0.015-0.034) 0.024
qd: once a day; bid: twice a day; qwk: once a week; MAC: Mycobacterium avium complex; ART: antiretroviral therapy; CI: confidence interval
aAt baseline.
bAll patients on ART were on dual or mono therapy
cStudy 023 and 027 are two identically designed studies. We calculated weighted averages the number of subjects, follow-up time, and number of new MAC
events for the two studies.
dDuration on treatment
eThis study was originally designed with a 450 mg qd dosage but reduced to 300 mg qd after 9 months.
fMean follow-up time
gThe primary endpoints of this study were MAC symptoms and positive culture. We only included culture-positive events, to remain consistent with the other
studies, which all used positive MAC cultures as primary endpoints.
Table 2 Efficacy of MAC regimens by direct and adjusted indirect comparison
Drug dose and study Method of efficacy
derivation
Study used for
comparison
Correction
factor
Adjusted monthly probability
of failure
% Efficacy
(95% CI)
Rifabutin, 300 mg, qd
Nightingale 1993 [13] Direct –– – 53 (48-61)
Havlir 1996 [17] Adjusted indirect Oldfield 1998 0.979
a 0.014 44
Benson 2000 [16] Adjusted indirect Pierce 1996 0.879
b 0.007 41
Clarithromycin, 500 mg, bid
Pierce 1996 [14] Direct –– – 66 (61-74)
Benson 2000 [16] Adjusted indirect Nightingale 1993 1.542
c 0.007 73
Azithromycin, 1200 mg, qwk
Oldfield 1998 [15] Direct –– – 66 (60-81)
Havlir 1996 [17] Adjusted indirect Nightingale 1993 0.896
d 0.007 72
Comparison of the monthly failure probabilities of:
aCompared to azithromycin in Oldfield 1998 [15].
bCompared to clarithromycin in Pierce 1996 [14]
cCompared to rifabutin in Nightingale 1993 [13]
dCompared to rifabutin in Nightingale 1993[13]
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rifabutin arms in each study [13,17], we estimated the
efficacy of azithromycin in the Havlir et al.t ob e7 2 % ,
compared to the Nightingale et al. placebo arm.
Comparison of direct and adjusted indirect comparison
methods
The efficacies of clarithromycin and azithromycin
derived by adjusted indirect comparison were not signif-
icantly different from the efficacies derived by direct
comparison. However, our estimate of the efficacy of
rifabutin by indirect comparison (41-44%) was signifi-
cantly lower than the efficacy derived by direct calcula-
tion (53%).
Discussion
This paper illustrates a simple method that can be used
to estimate input values for auxiliary parameters in mul-
tidimensional cost-effectiveness models. Since thorough
methodological expertise in indirect comparisons may
not always be accessible, the method illustrated in this
paper could be used to derive efficacy of treatments
where direct trials based on data are not readily avail-
able. To establish the efficacy of a drug regimen, it is
necessary to compare outcomes for patients on and off
therapy. While it is sometimes possible to derive this
information directly from the results of randomized
controlled trials, clinical trials are expected to provide
enrolled participants with the best proven treatment, or
at least the standard of care [4]. Thus, most studies
compare different treatment options; studies that admin-
ister placebo to some subjects despite existing and
accepted treatment options for the disease of interest
lack equipoise and therefore are not ethical or feasible
[4]. In this paper we have illustrated a simple method
for indirectly estimating the dose-specific efficacy of
drug regimens from reported results of randomized con-
trolled trials without placebo arms by a straightforward
adjustment for baseline clinical severity. When possible,
we estimated the efficacies directly from the trials.
We found that the derived adjusted indirect efficacies
of clarithromycin and azithromycin were similar to cor-
responding direct efficacies. However, the indirect effi-
cacy of rifabutin was significantly lower than the efficacy
derived by direct comparison. Unlike most other studies
used in this analysis, the Nightingale et al.s t u d y
reported mean duration on treatment, which is shorter
than mean follow-up time. This substitution may there-
fore have led to an overestimation of the direct efficacy
of rifabutin. The greater efficacy of rifabutin in the
direct comparison may also be attributed to the greater
proportion of patients on ART in this trial.
Our proposed method was consistent with that of pre-
vious studies showing that adjusted indirect comparison
reduces bias in drug efficacy calculations [5-7,11]. Our
inclusion criteria were stricter than those in previous
studies, because we examined outcomes only from trials
that compared drug regimens with specific doses and
that provided results at several time points. Thus, we
avoided having to pool results from various doses of the
same drug regimen. Our results may be more accurate
than previous studies for the specific doses examined,
since we only included trials that administered the doses
recommended in the United States “Guidelines for Pre-
vention and Treatment of Opportunistic Infections in
HIV-Infected Adults and Adolescents”[12]. Similar
results may be obtained using Indirect Treatment Com-
parisons (ITC) Software from the Canadian Agency for
Drugs and Health Technologies [18]. While this offers a
means of validation of the methods in this paper, a
step-by-step description may be useful to those who do
not have direct access to the ITC software, or for
further understanding of the insights provided.
One of the main purposes of the indirect comparisons
is to make stronger inferences about comparisons being
studied. We recognize the scarcity of placebo-controlled
trials in the HIV/AIDS field, particularly among newer
trials, and we believe that using older placebo-controlled
trials, as we have done in our illustration, for the purpose
of adjusted indirect comparisons, is acceptable. Our
study was limited by the number of studies that could be
used to derive OI prophylaxis efficacy. Only five studies
met the inclusion criteria. However, because the focus of
this analysis was to illustrate simple and replicable meth-
odology for adjusted indirect comparison of drug regi-
mens, the small number of included studies does not
deter from this goal. Moreover, two studies did not
report follow-up time [13,15]. For these studies, we cal-
culated efficacy by substituting follow-up time with mean
duration on treatment to calculate efficacy. The Oldfield
et al. study was terminated early because administering
placebo became inappropriate when the results of a sepa-
rate azithromycin efficacy trial [15]. It may be reasonable
to assume that most patients were on treatment at the
time of study discontinuation, and thus that the unre-
ported mean follow-up time is very similar to the mean
duration on treatment. However, treatment duration in
the Nightingale et al. study may have been greater than
the true unreported mean follow-up time, and could
have led to an overestimation of the efficacy of rifabutin.
While this method offers a useful approach for derivation
of point estimates, an extensive set of sensitivity analyses
are necessary to examine the robustness of policy conclu-
sions to uncertainty in parameter values. If a parameter is
influential, more sophisticated methods should be
employed to obtain a more precise value of parameter.
The prevalence of MAC and other opportunistic infec-
tions among HIV-infected patients in the United States
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of the HIV epidemic, due to the success of combination
antiretroviral therapy [19]. However, methods presented
in this study continue to be applicable to resource-
limited settings, where the use of opportunistic infection
prophylaxis in the absence of ART is still widespread. In
these areas, the WHO recommends lifelong prophylaxis
for fungal and bacterial infections, as well as for Pneu-
mocystis carinii Pneumonia with drugs such as flucona-
zole and cotrimoxazole [20]. In the United States,
recommendations for the prevention of opportunistic
infections continue to be revised regularly in the
national guidelines [12,21,22]. Similar indirect compari-
son methods may be useful in comparing effective first-
line antiretroviral regimens in the United States and in
many countries–such as those containing efavirenz, dar-
unavir, atazanavir, and raltegravir in the United States–
that have not been compared directly with each other
[23-25]. These methods can also be used to compare
second-line or subsequent ART regimens when efficacy
data have been published but direct comparisons may
have not been done.
Conclusion
The methodology demonstrated in this study is applic-
able to policy and implementation research, for which it
is necessary to know the absolute efficacy of specific
doses of pharmaceutical interventions as compared to
no intervention, to predict the outcomes of treatment
policies. As treatment options for HIV disease, both in
terms of opportunistic infection prophylaxis and ART,
continue to grow, these methods can help estimate effi-
cacies across a wide range of available and useful thera-
peutic regimens.
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